Blood group type A secretors are associated with a higher risk of COVID-19 cardiovascular disease complications.

Autor: Mankelow TJ; Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.; NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK., Singleton BK; Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.; NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK., Moura PL; Center for Hematology and Regenerative Medicine Department of Medicine (MedH) Karolinska Institutet Stockholm Sweden., Stevens-Hernandez CJ; Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.; NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK.; School of Biochemistry Biomedical Sciences Building University of Bristol Bristol UK., Cogan NM; Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.; NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK., Gyorffy G; Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.; NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK.; School of Biochemistry Biomedical Sciences Building University of Bristol Bristol UK., Kupzig S; Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.; NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK., Nichols L; Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK., Asby C; Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK., Pooley J; Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK., Ruffino G; Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK., Hosseini F; Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK., Moghaddas F; Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK., Attwood M; Infection Sciences, Southmead Hospital North Bristol NHS Trust Bristol UK., Noel A; Infection Sciences, Southmead Hospital North Bristol NHS Trust Bristol UK., Cooper A; Infection Sciences, Southmead Hospital North Bristol NHS Trust Bristol UK., Arnold DT; Infection Sciences, Southmead Hospital North Bristol NHS Trust Bristol UK., Hamilton F; Infection Sciences, Southmead Hospital North Bristol NHS Trust Bristol UK.; Population Health Sciences University of Bristol Bristol UK., Hyams C; Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK.; Academic Respiratory Unit Southmead Hospital North Bristol NHS Trust Bristol UK.; Population Health Sciences University of Bristol Bristol UK., Finn A; Cellular and Molecular Medicine Biomedical Sciences Building, University of Bristol Bristol UK.; Population Health Sciences University of Bristol Bristol UK.; Bristol Vaccine Centre University of Bristol Bristol UK., Toye AM; Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.; NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK.; School of Biochemistry Biomedical Sciences Building University of Bristol Bristol UK., Anstee DJ; Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.; NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK.; School of Biochemistry Biomedical Sciences Building University of Bristol Bristol UK.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2021 May; Vol. 2 (2), pp. 175-187. Date of Electronic Publication: 2021 Apr 02.
DOI: 10.1002/jha2.180
Abstrakt: The SARS-CoV-2 virus causes COVID-19, an infection capable of causing severe disease and death but which can also be asymptomatic or oligosymptomatic. We investigated whether ABO blood group or secretor status was associated with COVID-19 severity. We investigated secretor status because expression of ABO glycans on secreted proteins and non-erythroid cells are controlled by a fucosyltransferase (FUT2), and inactivating FUT2 mutations result in a non-secretor phenotype which protects against some viral infections. Data combined from healthcare records and our own laboratory tests ( n  = 275) of hospitalized SARS-CoV-2 polymerase chain reaction positive patients confirmed higher than expected numbers of blood group A individuals compared to O (RR = 1.24, CI 95% [1.05, 1.47], p  = 0.0111). There was also a significant association between group A and COVID-19-related cardiovascular complications (RR = 2.56, CI 95% [1.43, 4.55], p  = 0.0011) which is independent of gender. Molecular analysis revealed that group A non-secretors are significantly less likely to be hospitalized than secretors. Testing of convalescent plasma donors, among whom the majority displayed COVID-19 symptoms and only a small minority required hospitalization, group A non-secretors were slightly over-represented. Our findings showed that group A non-secretors are not resistant to infection by SARS-CoV-2, but are more likely to experience a less severe form of associated disease.
Competing Interests: The authors declare no competing financial interests.
(© 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: